Page 27 - Neil Kumar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neil Kumar, cofounder and CEO of BridgeBio, a company today valued at more than $10 billion, shares an embarrassing experience of the startup’s...

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership April 1, 2021 BridgeBio Pharma will join with Swiss pharma Helsinn Group to co-develop and commercialize infigratinib (BGJ398) in oncology and other indications except achondroplasia and other skeletal dysplasias, through a partnership that could generate up to approximately $2.45 billion for BridgeBio. [Helsinnn Group] Share BridgeBio Pharma will join with Swiss pharma Helsinn Group to co-develop and commercialize infigratinib (BGJ398) in oncology and other indications except achondroplasia and other skeletal dysplasias, through a p...

This story is available exclusively to Insider subscribers. Become an Insider and start reading now. The FDA approved BridgeBio's first drug, for a disease that affects 100 children in the US and Europe. BridgeBio mitigates risk with a "hub-and-spoke" model, with a central management team and subsidiaries. The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says. It wasn't that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts.  But these days, CEO Neil Kumar says he's taking calls...

Published: Mar 01, 2021 By Brandon May Rafael Henrique/SOPA Images/LightRocket via Getty Images The U.S. Food and Drug Administration (FDA) has approved BridgeBio Pharma and its affiliate Origin Biosciences’ injectable, rare genetic metabolic disorder therapy NULIBRY™ (fosdenopterin). This approval marks the first treatment indicated for reducing mortality risk in patients with the rare disorder known as molybdenum cofactor deficiency (MoCD) Type A. An ultra-rare and progressive disease, MoCD Type A affects fewer than 150 patients across the globe. Overall, the median survival fo...

The following is a review of The Transgender-Industrial Complex by Scott Howard (Antelope Hill Publishing, 2020). “In the wasteland of deepening darkness overcoming our civilization, the plagues of opioids and antidepressants, a steady diet of appointments with the local psychoanalyst, hormone blockers for prepubescent children, demon-drag-queen story time and more untold horrors confront us as the forces of disintegration eat the remnants of our civilization from the inside out.” With The Transgender-Industrial Complex, Scott Howard has given decent, red-blooded Heritage Americans one ...